Year 2018, Volume , Issue , Pages 22 - 30 2018-06-05

Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts

Erkan YULA [1] , Fatih KÖKSAL [2]


It has been well-known that several microorganisms that have an effect on particular areas of the body might additionally have systemic sequelae. In the last ten years, various studies have been performed on the relationship between Helicobacter pylori infection and a variety of extra digestive illnesses including immunological, hematological, neurological disorders and different pathologies. It has been recommended that complicated interactions between bacterial and host genetic factors, as well as environmental factors, play considerable roles in determining different clinical outcomes.  Although, there are conflicting and controversy data in some diseases, in the light of literature, it is currently accepted; that the presence or absence of H. pylori infection might influence the chance of developing of many autoimmune diseases. Treatment of H. pylori infection has been reported to be effective in some diseases like Schoenlein-Henoch purpura, ITP, psoriasis and chronic autoimmune urticaria. This review focuses the possible role of H. pylori infections in various autoimmune diseases taking into account the recent literature.

Helicobacter pylori, extraintestinal manifestations, autoimmune diseases
  • 1. Yula E, Nagiyev T, Kaya OA, Inci M, Celik MM, Köksal F. Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome. Folia Microbiol 2013; 58: 141-146.
  • 2. Nagiyev T, Yula E, Abayli B, Koksal F. Prevalence and genotypes of Helicobacter pylori in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova Region of Turkey. J Clin Microbiol 2009; 47: 4150-4153.
  • 3. Nagiyev T, Köksal F, Abaylı B, Yula E. [Comparison of culture and GlmM-PCR Methods for detecting Helicobacter pylori in antral and corpus biopsy specimens in patients with gastroduodenal disorders]. Turkiye Klinikleri J Med Sci 2010; 30: 919-924.
  • 4. Yula E, Nağiyev T, Köksal F, [Comparation of two different primer sets used for detection Helicobacter pylori DNA by polymerase chain reaction assay in gastric tissues], Turkiye Klinikleri J Med Sci 2010; 30: 1166-1170.
  • 5. Moodley Y, Linz B, Yamaoka Y, Windsor HM, Breurec S, Wu JY, Maady A, et al. The peopling of the Pacific from a bacterial perspective. Science 2009, 323: 527-530.
  • 6. Miernyk K, Morris J, Bruden D, McMahon B, Hurlburt D, Sacco F, et al. Characterization of Helicobacter pylori cagA and vacA genotypes among Alaskans and their correlation with clinical disease. J Clin Microbiol 2011; 49: 3114-3121.
  • 7. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatology diseases. Eur J Dermatol 2009; 19: 431-444.
  • 8. Negrini R, Savio A, Poiesi C, Appelmelk BJ, Buffoli F, Paterlini A, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996; 111: 655-665.
  • 9. Fae KC, Diefenbach da Silva D, Bilate AM, Tanaka AC, Pomerantzeff PMA, Kiss MH, et al. PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular tissue, are the target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients. J Autoimmun 2008; 31: 136-141.
  • 10. Kim SY, Lee YC, Kim HK, Blaser MJ. Helicobacter pylori CagA transfection of gastric epithelial cells induces interleukin-8. Cell Microbiol 2006; 8: 97-106.
  • 11. Eli Magen, Jorge-Shmuel Delgado. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol 2014; 20: 1510-1516.
  • 12. Gong Y, Tao L, Jing L, Liu D, Hu S, Liu W, et al. (2016) Association of TLR4 and Treg in Helicobacter pylori colonization and inflammation in mice. PLoS ONE 11(2): e0149629.
  • 13. Müller A, Oertli M, Arnold IC. H. pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection. Cell Communication and Signaling 2011; 9: 25.
  • 14. Ram M, Barzilai O, Shapira Y, et al. Helicobacter pylori serology in autoimmune diseases-fact or fiction? Clin Chem Lab Med 2013; 51: 1075–1082.
  • 15. Lim JH, Kim N, Lim SH, Kwon JW, Shin CM, Chang YS, Kim JS, Jung HC, Cho SH. Inverse Relationship Between Helicobacter pylori Infection and Asthma Among Adults Younger than 40 Years: A Cross-Sectional Study. Medicine (Baltimore). 2016; 95(8): e2609.
  • 16. Yula E, Tok YT, Kalkan T, Gökmen AA, Balık R, Baran N, Sener AG et al. Comparison of active Helicobacter pylori infection rate and CagA virulence marker positivity in patients with various autoimmune diseases; first results. Turk J Immunol 2016; 4 (Suppl 1): 70.
  • 17. El-Hewala ASI, Khamis SS, Soliman SG, Alsharaki DR, Abd El-Raof Salman MM. Study of the effect of treatment of Helicobacter pylori on rheumatoid arthritis activity. Menoufia Med J 2015; 28: 319-324.
  • 18. Tanaka E, Singh G, Saito A, Syouji A, Yamada T, Urano W, et al. Prevalence of Helicobacter pylori infection and risk of upper gastrointestinal ulcer in patients with rheumatoid arthritis in Japan. Mod Rheumatol 2005;15: 340-345.
  • 19. Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, et al. Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism related disorders 2015; 21: 221-225.
  • 20. Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PLoS One 2014; 9: e112330.
  • 21. Blaecher C, Smet A, Flahou B, Pasmans F, Ducatelle R, Taylor D, et al. Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Pharmacol Ther 2013; 38: 1347-1353.
  • 22. Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, et al. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008; 13: 309-322.
  • 23. Gavalas E, Kountouras J, Boziki M, Zavos C, Polyzos SA, Vlachaki E, et al. Relationship between Helicobacter pylori infection and multiple sclerosis. Ann Gastroenterol 2015; 28: 353-356.
  • 24. Boziki M, Grigoriadis N, Deretzi G, Lagoudaki R, Lourbopoulos A, Panayotopoulou E et al. Helicobacter pylori immunomodulative properties in a mouse model of multiple sclerosis. Immunogastroenterology. 2012; 1: 34-39.
  • 25. Long Y, Gao C, Qiu W, Hu X, Shu Y, Peng F, Lu Z. Helicobacter pylori infection in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 2013; 20: 107-112.
  • 26. Gang Yaoa, Ping Wangc, Xiang-Dan Luo, Ting-Min Yu, Robert A. Harris, Xing-Mei Zhang. Meta-analysis of association between Helicobacter pylori infection and multiple sclerosis. Neuroscience Letters. 2016; 620: 1-7.
  • 27. A Gasbarrinia, F Franceschia, A Armuzzib, V Ojettib, M Candellib, E Sanz Torreb, A De Lorenzoc, et al. Extradigestive manifestations of Helicobacter pylori gastric infection. Gut 1999; 45: I9-I12.
  • 28. Sagar V, Zafar KS, Kumar G. A study of Helicobacter pylori infection in patients of ischemic cerebro vascular stroke. Int J Res Med Sci 2016; 4: 589-592.
  • 29. Lin Y, Obata Y, Kikuchi S, Tamakoshi, Iso H, JACC Study Group. Helicobacter pylori infection and risk of death from cardiovascular disease among the Japanese Population: a Nested Case-Control Study within the JACC Study. Journal of Atherosclerosis and Thrombosis 2015; 22: 1-7.
  • 30. Nam SY, Ryu KH, Park BJ, Park S. Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter 2015; 20: 125-132.
  • 31. Tebbe B, Geilen CC, Schulzke JD, Bojarski C, Radenhausen M, Orfanos CE. Helicobacter pylori infection and chronic urticaria. J Am Acad Dermatol 1996; 34:685-686.
  • 32. Sharma VK, Lynn A, Kaminski M, Vasudeva R, Howden CW. A study of the prevalence of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea. Am J Gastroenterol 1998; 93: 220-222.
  • 33. Tosti A, Pretolani S, Figura N, Polini M, Cameli N, Cariani G, et al. Helicobacter pylori and skin diseases. Gastroenterology International 1997; 10: 37-39.
  • 34. Danese S, Zoli A, Cremonini F, Gasbarrini A. High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol 2000; 27: 1568-1569.
  • 35. Frydman GH, Davis N, Beck PL, Fox JG. Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: A review and the role of biogeography. Helicobacter 2015; 20: 239-251.
  • 36. Brito HSH, Braga JAP, Loggetto SR, Machado RS, Granato CFH, Kawakami K. Helicobacter pylori infection and immune thrombocytopenic purpura in children and adolescents: A randomized controlled trial. Platelets 2015; 26(4): 336-341.
  • 37. Ali AM, Ayman MN, Mahmoud MA. Helicobacter pylori Infection and its Potential Role in Childhood Eczema. J Immunol Tech Infect Dis 2016, 5:1.
  • 38. B. Taye, F. Enquselassie, A. Tsegaye, G. Medhin, G. Davey, A. Venn. Is Helicobacter pylori infection inversely associated with atopy? A systematic review and meta-analysis. Clinical and Experimental Allergy 2015: 45; 882–890.
  • 39. Campanati, A., Ganzetti, G., Martina, E., Giannoni, M., Gesuita, R., Bendia, E., Giuliodori, K., Sandroni, L. and Offidani, A. (2015), Helicobacter pylori infection in psoriasis: results of a clinical study and review of the literature. Int J Dermatol 54: e109–e114.
  • 40. AG Gravina, A Federico, E Ruocco, A Lo Schiavo, M Masarone, C Tuccillo et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterol J 2015; 3: 17-24.
  • 41. Burstein R, Noseda R, Borsook D. Migraine: Multiple Processes, Complex Pathophysiology. Journal of Neuroscience 2015: 35: 6619-6629.
  • 42. Anderson G, Maes M. Melatonin: a natural homeostatic regulator - interactions with immune inflammation and trytophan catabolite pathways in the modulation of migraine and endometriosis. Journal of Natural Products Research Updates 2015; 1: 7-17.
  • 43. Tanik N, Celikbilek A, Metin A, Gocmen AY, Inan LE. Retinol-binding protein-4 and hs-CRP levels in patients with migraine. Neurol Sci.October 2015; 36: 1823-1827.
  • 44. Yilmaz IA, Ozge A, Erdal ME, Edgünlü TG, Cakmak SE, Yalin OO. Cytokine polymorphism in patients with migraine: some suggestive clues of migraine and inflammation. Pain Med 2010; 11: 492-497.
  • 45. La Mantia L, Prone V. Headache in multiple sclerosis and autoimmune disorders. Neurol Sci 2015; 36: 75-78.
  • 46. Gasbarrini A, Gabrielli M, Fiore G, Candelli M, Bartolozzi F, De LA, et al. Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia. 2000; 20: 561-565.
  • 47. Faraji F, Zarinfar N, Zanjani AT, Morteza A. The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain Physician 2012; 15: 495-498.
  • 48. Behnaz Ansari, Keivan Basiri, Rokhsareh Meamar, Ahmad Chitsaz, Shahrzad Nematollahi. Association of Helicobacter pylori antibodies and severity of migraine attack. Iran J Neurol 2015; 14: 125-129.
  • 49. Mann NS, Singh S. Helicobacter Pylori and Migraine: systematic evaluation of 1084 cases with meta-analysis. International Medical Journal 2015; 22: 65-66.
  • 50. Roubaud Baudron C , Varon C , Mégraud F , Salles N. Alzheimer's disease and Helicobacter pylori infection: a possible link? Geriatrie et Psychologie Neuropsychiatrie du Vieillissement 2016; 14: 86-94.
  • 51. Judith Miklossy, Patrick L. McGeer. Common mechanisms involved in Alzheimer’s disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging 2016; 8: 575-588.
  • 52. Vitale G, Barbaro F, Ianiro G, et al. Nutritional aspects of Helicobacter pylori infection. Minerva Gastroenterol Dietol 2011; 4: 369-377.
  • 53. Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, Yan X et al. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. Journal of Alzheimer's Disease 2015; 43: 153-165.
  • 54. Faldu KG, Shah JS, Patel SS. Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer's Disease. Recent Pat Antiinfect Drug Discov 2015; 10: 76-83.
  • 55. Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus: a risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries 2010; 30: 22-26.
  • 56. Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol. 2007; 18: 225-229.
  • 57. Anastasios R, Goritsas C, Papamihail C, Trigidou R, Garzonis P, Ferti A. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002; 13: 376.
  • 58. Nasif WA, Mukhtar MH, Eldein MMH, Ashgar SS. Oxidative DNA damage and oxidized low density lipoprotein in Type II diabetes mellitus among patients with Helicobacter pylori infection. Diabetol Metab Syndr 2016; 8: 34.
  • 59. Gerig R, Ernst B, Wilms B, Thurnheer M, Schultes B. Gastric Helicobacter pylori infection is associated with adverse metabolic traits in severely obese subjects. Obesity 2013; 21: 535-537.
  • 60. Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, Leonetti F, Severi C. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450-1454.
  • 61. Adler I, Denninghoff VC, Alvarez MI, Avagnina A, Yoshida R, Elsner B. Helicobacter pylori associated with glossitis and halitosis. Helicobacter 2005; 10: 312-317.
  • 62. Esfahani AM, Irani S, Sabeti S, Zerehpoush FB. The Possible Role of Helicobacter pylori in the Development of Sjogren's Syndrome and Chronic Sialadenitis. Avicenna J Dent Res 2015; 7: e23212.
  • 63. Gülseren D, Karaduman A, Kutsal D, Nohutcu RM. The relationship between recurrent aphthous stomatitis, and periodontal disease and Helicobacter pylori infection. Clinical Oral Investigations. 2016. In press. DOI: 10.1007/s00784-015-1704-0
  • 64. Lender N, Talley, Enck P, Haag S, Zipfel S, Morrison M, GJ Holtmann NJ. Review article: associations between Helicobacter pylori and obesity - an ecological study. Aliment Pharmacol Ther 2014; 40: 24-31.
  • 65. Arslan E, Atilgan H, Yavaşoğlu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med 2009; 20: 695– 697.
  • 66. Adriani A, Repici A, Hickman I, Pellicano R. Helicobacter pylori infection and respiratory diseases: actual data and directions for future studies. Minerva Med 2014; 105: 1-8.
  • 67. Malfertheiner MV, Kandulski A, Schreiber J, Malfertheiner P. Helicobacter pylori infection and the respiratory system: A systematic review of the literature. Digestion 2011; 84: 212-220.
  • 68. den Hollander WJ, Sonnenschein-van der Voort AM, Holster IL, de Jongste JC, Jaddoe VW, Hofman A, et al. Helicobacter pylori in children with asthmatic conditions at school age, and their mothers. Aliment Pharmacol Ther 2016, Mar 1. doi: 10.1111/apt.13572.
  • 69. Rokkas T, Gisbert JP, Niv Y, O’Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterology J 2015; 3: 539-550.
Primary Language en
Subjects Medicine
Journal Section Review Article
Authors

Author: Erkan YULA (Primary Author)
Institution: İZMİR KATİP ÇELEBİ ÜNİVERSİTESİ

Author: Fatih KÖKSAL

Dates

Publication Date : June 5, 2018

Bibtex @review { jicm422124, journal = {Journal of Immunology and Clinical Microbiology}, issn = {}, eissn = {2528-9470}, address = {Adalet mh. 1643/18 Sk. bina no:6 smyrnapark evleri b blok daire 16, Bayraklı, İzmir}, publisher = {Erkan YULA}, year = {2018}, volume = {}, pages = {22 - 30}, doi = {10.5455/jicm.10.20160627}, title = {Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts}, key = {cite}, author = {YULA, Erkan and KÖKSAL, Fatih} }
APA YULA, E , KÖKSAL, F . (2018). Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts. Journal of Immunology and Clinical Microbiology , () , 22-30 . DOI: 10.5455/jicm.10.20160627
MLA YULA, E , KÖKSAL, F . "Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts". Journal of Immunology and Clinical Microbiology (2018 ): 22-30 <https://dergipark.org.tr/en/pub/jicm/issue/36924/422124>
Chicago YULA, E , KÖKSAL, F . "Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts". Journal of Immunology and Clinical Microbiology (2018 ): 22-30
RIS TY - JOUR T1 - Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts AU - Erkan YULA , Fatih KÖKSAL Y1 - 2018 PY - 2018 N1 - doi: 10.5455/jicm.10.20160627 DO - 10.5455/jicm.10.20160627 T2 - Journal of Immunology and Clinical Microbiology JF - Journal JO - JOR SP - 22 EP - 30 VL - IS - SN - -2528-9470 M3 - doi: 10.5455/jicm.10.20160627 UR - https://doi.org/10.5455/jicm.10.20160627 Y2 - 2019 ER -
EndNote %0 Journal of Immunology and Clinical Microbiology Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts %A Erkan YULA , Fatih KÖKSAL %T Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts %D 2018 %J Journal of Immunology and Clinical Microbiology %P -2528-9470 %V %N %R doi: 10.5455/jicm.10.20160627 %U 10.5455/jicm.10.20160627
ISNAD YULA, Erkan , KÖKSAL, Fatih . "Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts". Journal of Immunology and Clinical Microbiology / (June 2018): 22-30 . https://doi.org/10.5455/jicm.10.20160627
AMA YULA E , KÖKSAL F . Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts. J Immunol Clin Microbiol. 2018; 22-30.
Vancouver YULA E , KÖKSAL F . Autoimmune extraintestinal manifestations of Helicobacter pylori infection: A bundle of conflicts. Journal of Immunology and Clinical Microbiology. 2018; 30-22.